Pancreatic Cancer Market Forecasts to 2030 – Global Analysis By Treatment Type (Radiation Therapy, Targeted Drug Therapy, Immunotherapy, Chemotherapy and Other Treatment Types), Diagnostic Tool (Computerized Tomography (CT) Scans, Magnetic Resonance Imagi

Pancreatic Cancer Market Forecasts to 2030 – Global Analysis By Treatment Type (Radiation Therapy, Targeted Drug Therapy, Immunotherapy, Chemotherapy and Other Treatment Types), Diagnostic Tool (Computerized Tomography (CT) Scans, Magnetic Resonance Imaging (MRI), Positron Emission Tomography (PET) Scans and Other Diagnostic Tools), End User (Diagnostic Laboratories, Hospitals and Other End Users) and By Geography

According to Stratistics MRC, the Global Pancreatic Cancer Market is accounted for $3.42 billion in 2024 and is expected to reach $9.13 billion by 2030 growing at a CAGR of 17.8% during the forecast period. Pancreatic cancer is a malignant neoplasm that originates in the tissues of the pancreas, an organ located behind the stomach. It is characterized by the abnormal and uncontrollable growth of cells in the pancreas, leading to the formation of tumors. Pancreatic cancer is often difficult to detect in its early stages, which contributes to its high mortality rate. Symptoms may not manifest until the disease has progressed significantly, and they can include abdominal pain, jaundice, unexplained weight loss, and digestive issues.

According to the America’s Cancer Society for pancreatic cancer, about 64,050 people will be diagnosed with pancreatic cancer in 2023 and estimation of around 50,550 people will die of pancreatic cancer.

Market Dynamics:

Driver:

Active involvement of patient advocacy groups

Active involvement of patient advocacy groups is playing a pivotal role in enhancing the Pancreatic Cancer Market by fostering awareness, driving research initiatives, and influencing policy changes. These groups serve as powerful advocates for patients, amplifying their voices and lobbying for increased funding and resources for pancreatic cancer research. Through their efforts, patient advocacy groups are not only raising public awareness about the disease but also mobilizing support for early detection methods and innovative treatments. Moreover, they facilitate collaboration among researchers, healthcare professionals, and pharmaceutical companies, accelerating the development of novel therapies and improving patient outcomes.

Restraint:

High treatment costs

High treatment costs significantly hinder the Pancreatic Cancer Market by posing a substantial barrier to access for patients. The complexity of the disease often requires prolonged treatment periods, further exacerbating financial burdens on patients and healthcare systems. However, the high costs not only deter patients from seeking timely medical care but also strain healthcare budgets, limiting the availability of resources for research and development of new therapies.

Opportunity:

Improvements in surgical techniques

Improvements in surgical techniques are significantly enhancing the pancreatic cancer market by offering more effective treatment options and better patient outcomes. Minimally invasive procedures, such as laparoscopic and robotic-assisted surgeries, have reduced postoperative complications, shortened recovery times, and improved patient comfort compared to traditional open surgeries. These advancements enable surgeons to perform complex pancreatic resections with greater precision and minimal damage to surrounding tissues, leading to improved survival rates and quality of life for patients.

Threat:

Lack of biomarkers for early detection

The absence of reliable biomarkers for early detection poses a significant obstacle in advancing the pancreatic cancer market. Unlike some other cancers where biomarkers aid in early diagnosis, pancreatic cancer often remains asymptomatic until it reaches advanced stages, making timely detection challenging. Consequently, patients are often diagnosed when the disease has already metastasized, severely limiting treatment options and reducing overall survival rates. Without effective biomarkers, clinicians lack the tools to identify pancreatic cancer in its initial stages when it's more treatable, hindering the development of targeted therapies and personalized treatment approaches.

Covid-19 Impact:

While the pandemic heightened the urgency for innovative treatments and accelerated research efforts, it also disrupted patient care and clinical trials. The diversion of healthcare resources towards managing Covid-19 strained cancer care services, leading to delayed diagnoses and treatment initiation for many pancreatic cancer patients. Restrictions on non-essential medical procedures and reduced patient visits to healthcare facilities resulted in a decline in screening and diagnostic procedures, potentially causing missed or delayed diagnoses of pancreatic cancer. However, the pandemic also prompted the adoption of telemedicine and remote monitoring solutions, offering some avenues for continued patient care and clinical trial participation amidst the challenges posed by Covid-19 restrictions.

The Radiation Therapy segment is expected to be the largest during the forecast period

Radiation Therapy segment is expected to be the largest during the forecast period. This therapy involves the use of high-energy radiation to destroy cancer cells and shrink tumors. In the case of pancreatic cancer, where surgical options are often limited due to late-stage diagnosis or tumor location, radiation therapy emerges as a crucial treatment modality. It can be employed preoperatively to shrink tumors, making them more manageable for surgical removal, or postoperatively to target any remaining cancer cells. Additionally, radiation therapy is often combined with other treatment modalities like chemotherapy to maximize its effectiveness.

The Magnetic Resonance Imaging (MRI) segment is expected to have the highest CAGR during the forecast period

Magnetic Resonance Imaging (MRI) segment is expected to have the highest CAGR during the forecast period. MRI offers superior soft tissue contrast, allowing for precise visualization of the pancreas and surrounding structures, facilitating early detection and accurate staging of pancreatic tumors. Its non-invasive nature and lack of ionizing radiation make it particularly advantageous for monitoring disease progression and treatment response. Moreover, advancements such as diffusion-weighted imaging and dynamic contrast-enhanced MRI have further improved the sensitivity and specificity of pancreatic cancer detection.

Region with largest share:

Asia Pacific region is estimated to hold the largest share of the Pancreatic Cancer Market over the extrapolated period of time. Effective reimbursement policies can facilitate broader patient access to costly yet potentially life-saving treatments such as chemotherapy, radiation therapy, and surgical interventions. By ensuring that healthcare costs are covered, these policies encourage healthcare providers to adopt advanced technologies and therapies, driving regional improvements in the quality of care for pancreatic cancer patients. Moreover, favorable reimbursement policies can incentivize pharmaceutical companies to invest in research and development efforts tailored to the region's specific healthcare needs, leading to the introduction of novel therapies and diagnostic tools.

Region with highest CAGR:

Asia Pacific region is projected to estimate the profitable growth during the forecasted period. Through stringent regulatory frameworks, governments are ensuring that pharmaceutical companies adhere to high standards of efficacy and safety in developing pancreatic cancer treatments throughout the region. Regulatory bodies are working towards expediting the approval process for new therapies, facilitating timely access to cutting-edge treatments for patients in the Asia Pacific region. Additionally, regulations promote transparency and fair competition among market players, which ultimately benefits consumers by offering a wider range of treatment options at competitive prices. These elements are boosting the regional growth.

Key players in the market

Some of the key players in Pancreatic Cancer market include Celgene Corporation, F. Hoffmann-La Roche AG, Midatech Pharma PLC, Eli Lilly and Company, Sun BioPharma, Inc, Oncolytics Biotech, Clovis Oncology, Polaris Pharmaceuticals, Inc, Pharmacyte Biotech Inc and Novartis International AG.

Key Developments:

In March 2023, Novartis is currently in Phase I of the clinical development of LGK-974 for metastatic pancreatic cancer. The phase transition success rate (PTSR) benchmark for moving into Phase II for Phase I drugs for Metastatic Pancreatic Cancer is 88%, according to GlobalData.

In December 2022, scientists developed the world's first early pancreatic cancer screening test, which utilizes worms to discover tumors. The test, which was initiated in Japan this month, claims to be 100% precise in detecting cancer and can trace it in its early stages.

In October 2022, Erasca, based extended its current collaboration with Pfizer to evaluate ERAS-007 when combined with Pfizer's Ibrance (palbociclib). Both biopharma will start clinical proof-of-concept research as part of the extended clinical trial collaboration and supply agreement.

In February 2022, A partnership between Eli Lilly and Company and UNICEF was announced with the goal of enhancing healthcare resources for the roughly 10 million children and adolescents with non-communicable diseases.

Treatment Types Covered:
• Radiation Therapy
• Targeted Drug Therapy
• Immunotherapy
• Chemotherapy
• Other Treatment Types

Diagnostic Tools Covered:
• Computerized Tomography (CT) Scans
• Magnetic Resonance Imaging (MRI)
• Positron Emission Tomography (PET) Scans
• Other Diagnostic Tools

End Users Covered:
• Diagnostic Laboratories
• Hospitals
• Other End Users

Regions Covered:
• North America
US
Canada
Mexico
• Europe
Germany
UK
Italy
France
Spain
Rest of Europe
• Asia Pacific
Japan
China
India
Australia
New Zealand
South Korea
Rest of Asia Pacific
• South America
Argentina
Brazil
Chile
Rest of South America
• Middle East & Africa
Saudi Arabia
UAE
Qatar
South Africa
Rest of Middle East & Africa

What our report offers:
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2022, 2023, 2024, 2026, and 2030
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements